Processed Amniotic Fluid (pAF) for the Treatment of Chronic Wounds

Phase 2TerminatedNCT04438174

University of Utah1 enrolled

Overview

A prospective randomized controlled study to determine the safety and feasibility of using processed amniotic fluid (pAF) to expedite healing in chronic wounds.

The goal of our study is to assess, in an outpatient setting, the safety and the time to wound closure in chronic wounds treated with processed amniotic fluid (pAF). We will include patients with lower extremity full thickness wounds that are greater than 3 months old and less than 12 months old. The wound size must be greater than 5cm2 and less than 75 cm2. We will exclude anyone that requires skin grafting, or wounds with sinus tracts. Our primary objective is to determine the safety and feasibility of using pAF to treat patients with chronic wounds. The secondary objective is to determine the efficacy of pAF compared to standard of care in reducing wound area.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Wounds and Injuries

Interventions

Processed Amniotic FluidDRUG

Injection of 1 ml of processed amniotic fluid per 5 cm2 of wound area

Standard of Care Wound Treatment RegimenOTHER

ointment-based dressing and non-ointment-based dressings

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients 18-85 years old. 2. Patients with chronic lower extremity wounds (including thermal) that are greater than 3 months, but less than 12 months old. 3. Patients with full thickness wounds. 4. Patients with at least one wound that is ≥5 cm2 and\<75 cm2 in size. 5. Patient who is able to complete required site study visits and procedures in good faith Exclusion Criteria: 1. Patients admitted to the hospital at the time of enrollment. 2. Patients who are pregnant, nursing or plan to become pregnant while participating in the study. If of child-bearing potential, unwillingness to use effective birth control while participating in the study. 3. Suspicion of or diagnosis of osteomyelitis underlying the wound. 4. Patients who have received an investigational agent or intervention within the prior 30 days or plan to use within the study period. 5. Patient with sinus tracts, enterocutaneous fistulas or other epithelialized tracts. 6. Patients who require skin grafting. 7. Patients diagnosed with a highly disruptive, non-controlled mental health disorder (e.g.., bipolar, or schizophrenia. 8. Patients with a history of prior drug abuse.

Locations (1)

University of Utah Burn Center

Salt Lake City, Utah, United States

Outcomes

Primary Outcomes

Safety - Adverse Events Including Serious Adverse Events

Safety and tolerability will be evaluated by the PI from the results of reported signs and symptoms and scheduled physical examinations. The primary endpoint is whether the patient experienced any post-randomization, study-related serious adverse event (SAEs) while on study (collections of new AEs begins at visit two and ends at visit five which is approximately, 7 months after enrollment). An SAE is considered study-related if the medical monitor concludes the SAE is either possibly related or probably related to study participation. Although unresolved SAE's were to be monitored for 1 year or until resolution, no SAEs were unresolved at the time of study completion (approximately, 7 months after enrollment).

Time frame: Approximately 7 months after enrollment

Secondary Outcomes

Feasibility - Reduction in Wound Size - Secondary Outcome Per Secondary Assessor

The percent reduction in wound area at Visit 5 (final visit) relative to the size at randomization visit (visit 2). Wound surface area will be calculated and maximal wound depth will also be measured using ImageJ overlay software technology. Two assessors examined the wound surface area at each visit using ImageJ. This is the outcome as reported by the secondary assessor. A negative value indicates an increase in wound size; a positive value indicates a decrease in wound size.

Time frame: Visit 2 (approximately 6 weeks after enrollment) and Visit 5 (approximately 7 months after enrollment)

Feasibility - Reduction in Wound Size - Secondary Outcome Per Primary Assessor

The percent reduction in wound area at Visit 5 (final visit) relative to the size at randomization visit (visit 2). Wound surface area will be calculated and maximal wound depth will also be measured using ImageJ overlay software technology. Two assessors examined the wound surface area at each visit using ImageJ. This is the outcome as reported by the primary assessor. A negative value indicates an increase in wound size; a positive value indicates a decrease in wound size.

Time frame: Visit 2 (approximately six weeks after enrollment) and Visit 5 (approximately 7 months after enrollment)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.